Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab plus axitinib neoadjuvant therapy in VHL-associated clear cell renal cell carcinoma
ChiCTR2000037024Phase 4Recruiting
- Sponsor
- Renji Hospital
- Start
- Oct 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of toripalimab and axitinib in clear cell renal cell carcinoma (ccRCC) and von Hippel–Lindau disease (VHL), sponsored by Renji Hospital. Primary endpoints: Objective response rate of kidney tumors at week 12, Safety – incidence of adverse events and 1 more. Started Oct 2020; status: recruiting.
02
Drugs
toripalimabaxitinib
03
Conditions
clear cell renal cell carcinoma (ccRCC)von Hippel–Lindau disease (VHL)
Beyond the preview
Go deeper on ChiCTR2000037024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000037024.